Merck announced on March 26, 2025, that the European Commission (EC) approved its pneumococcal vaccine CAPVAXIVE (Pneumococcal 21-valent Conjugate Vaccine). This approval is for the prevention of invasive pneumococcal disease and pneumococcal pneumonia in individuals 18 years of age and older.
The authorization applies to all 27 EU member states, as well as Iceland, Liechtenstein, and Norway. CAPVAXIVE was previously approved in the U.S. in June 2024, followed by Canada in July 2024, and Australia in January 2025.
This significant regulatory milestone expands Merck's global vaccine footprint and provides a new option for adult pneumococcal vaccination in Europe. CAPVAXIVE is designed to protect against serotypes predominantly responsible for adult invasive pneumococcal disease.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.